GSK's Bepirovirsen Achieves Unprecedented Phase 3 Functional Cure Rates for Chronic Hepatitis B
Summary
GSK announced groundbreaking Phase 3 results for bepirovirsen, showing unprecedented functional cure rates for chronic hepatitis B, a major global health challenge.
Key Events
-
Pivotal Phase 3 Data Released
Bepirovirsen achieved a 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, significantly exceeding the <1% rate of current standard of care.
-
Potential to Redefine CHB Treatment
Functional cure, defined as undetectable HBV DNA and HBsAg, is associated with an 89% reduction in liver cancer risk and a 62% reduction in all-cause mortality, offering a major advance for the 240 million people affected by chronic hepatitis B.
-
Strong Regulatory Momentum
The drug is currently under priority review by the US FDA (with Breakthrough and Fast Track Designations), EMA, Japan, and China, with first regulatory decisions anticipated in Q3 2026.
-
Acceptable Safety Profile
The trials showed an acceptable safety and tolerability profile consistent with previous studies.
Analysis
This filing announces highly positive pivotal Phase 3 data for bepirovirsen, an investigational treatment for chronic hepatitis B (CHB). The reported functional cure rates of 19% and 26% significantly surpass the current standard of care (<1%), representing a major medical advance for a disease affecting over 240 million people worldwide and a leading cause of liver cancer. This strong clinical data substantially de-risks the ongoing regulatory reviews in major markets and positions bepirovirsen as a potential first-in-class treatment, which could be a significant revenue driver for GSK.
At the time of this filing, GSK was trading at $51.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $103.8B. The 52-week trading range was $35.45 to $61.70. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.